Asset
ABIPRUBART
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC CLASS A ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06531395 | phase2 | terminated | 2024-07-17 | 2025-03-06 | Kiniksa Pharmaceuticals International, plc | A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease |
| NCT05198310 | phase2 | completed | 2021-12-14 | 2024-02-08 | Kiniksa Pharmaceuticals, Ltd. | Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
| NCT04497662 | phase1 | completed | 2019-10-22 | 2021-01-21 | Kiniksa Pharmaceuticals, Ltd. | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects |
FDA applications (0)
This company has no applications containing this asset.